TLR7抗体;TLR7 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using TLR7 mouse mAb (green) and negative control (red).    

  
  

Toll-like receptor 7 (TLR7) is a pattern recognition receptor within the innate immune system, primarily localized in endosomal membranes of immune cells like dendritic cells and B lymphocytes. It recognizes single-stranded RNA (ssRNA) from viruses such as influenza and SARS-CoV-2. triggering MyD88-dependent signaling pathways that drive the production of pro-inflammatory cytokines (e.g., IFN-α, TNF-α, IL-6) and promote adaptive immune responses. Dysregulated TLR7 activation is implicated in autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), where aberrant self-RNA sensing leads to chronic inflammation. Conversely, TLR7 agonists are explored as vaccine adjuvants or anticancer agents to enhance immune activation.

TLR7 antibodies are critical tools for studying its expression, localization, and functional roles. Neutralizing antibodies can inhibit TLR7 signaling, offering therapeutic potential in autoimmunity by blocking pathogenic cytokine release. Conversely, agonist antibodies may mimic ligand binding to amplify antiviral or antitumor responses. In drug development, monoclonal antibodies targeting TLR7 or its downstream effectors are being evaluated in preclinical and clinical trials. Challenges include balancing therapeutic efficacy with off-target effects, given TLR7's dual role in protection and pathology. Overall, TLR7 antibodies bridge mechanistic research and targeted therapies, reflecting their growing importance in immunology and translational medicine.